Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00031629 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus
A Phase 2 study of Uterine Corpus Leiomyosarcoma and Recurrent Uterine Corpus Sarcoma, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
- 1
- Study location
NCT00031629: Completed Phase 2 study of Uterine Corpus Leiomyosarcoma and Recurrent Uterine Corpus Sarcoma, sponsored by Gynecologic Oncology Group.
NCT00031629 is a Phase 2 study of Uterine Corpus Leiomyosarcoma and Recurrent Uterine Corpus Sarcoma that has completed, run by Gynecologic Oncology Group. The registered enrollment target is 51 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00031629, a Phase 2 study of Uterine Corpus Leiomyosarcoma and Recurrent Uterine Corpus Sarcoma, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
- 1
- Study location
Study Summary
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Colony-stimulating factors such as filgrastim or pegfilgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. This phase II trial is studying how well combination chemotherapy plus filgrastim or pegfilgrastim works in treating patients with recurrent or persistent cancer of the uterus.
Conditions Studied
Interventions
- DRUG Docetaxel
- BIOLOGICAL Filgrastim
- BIOLOGICAL Pegfilgrastim
- DRUG Gemcitabine Hydrochloride
Study Locations (1)
Pennsylvania
- Gynecologic Oncology Group - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2005-01 |
| Phase | Phase 2 |
What the finished NCT00031629 record still lists
NCT00031629 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower).
The record links to 2 conditions, with Uterine Corpus Leiomyosarcoma appearing as the primary indexed condition, and to 4 interventions - of which Docetaxel is the first listed.
NCT00031629 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00031629 about?
NCT00031629 is a clinical study titled "Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus". Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Colony-stimulating factors such as filgrastim or pegfilgrastim may increase the number of immune cells found in bone marrow or peripher...
What is the current status of trial NCT00031629?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2005-01.
What conditions does trial NCT00031629 study?
This clinical trial studies the following conditions: Uterine Corpus Leiomyosarcoma, Recurrent Uterine Corpus Sarcoma.
What interventions are being tested in trial NCT00031629?
The interventions under investigation include: Docetaxel (DRUG), Filgrastim (BIOLOGICAL), Pegfilgrastim (BIOLOGICAL), Gemcitabine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00031629?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00031629 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uterine Corpus Leiomyosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00031629's enrollment target sits among peer trials
51 1190th of 2000 higher than 806 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia